Companies Compete Over Mutation-Specific Melanoma Drugs

March 10, 2011


Lynn Schuchter, MD, chief of the division of Hematology/Oncology, is quoted in a Nature Medicine story about B-RAF inhibitors, the new generation of melanoma drugs nearing approval that target a common mutation implicated in driving tumor growth. The drugs are revolutionized the way physicians treat the metastatic form of the disease. We've never seen anything like this," says Schuchter, who has been involved in trials of several of these mutation-specific drugs. "We really have tears of joy." Read More

Related Information